A Phase 3 interventional study of LF111 (drospirenone) in Contraception, sponsored by Laboratories Leon Farma, S.A.. Completed at 37 sites in United States. Open to female participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-06.
Sponsored by Laboratories Leon Farma, S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
This trial is a prospective, multicenter, open-label, non-controlled trial in female subjects, including adolescents between the ages of 15+(inclusive) who present to the clinic seeking contraception, who are postmenarcheal and premenopausal.
At screening, informed consent will be obtained and the screening procedures will be performed. After confirmation of the subject's eligibility, the subject will be provided with the investigational product and trained in the use of an electronic diary. Afterwards, the subjects will attend visit the clinical site on Day 20±2 of the 1st, 3rd, 6th and 9th cycles and on Day 29+2 of the 13th cycle. The last clinical site visit will occur 10-14 days after the 13th cycle visit.
The trial will include women who have never used hormonal contraceptives before consent (naïve users), women who have not used hormonal contraceptives in the past three months before consent or who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent (previous users) as well as women directly switching from another hormonal method (switchers). Women who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent are allowed to be included into the trial if they had at least one complete menstrual cycle before enrollment.
A population pharmacokinetic (PK) analysis planned in the whole subject population, will obtain sparse blood samples to determine plasma concentrations. In total, four blood samples will be collected: two samples each will be collected during the 1st cycle and during the 6th cycle of treatment.
Adverse events and safety information will be collected throughout the study.
This is the only study on the registry with Laboratories Leon Farma, S.A. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects at risk of pregnancy, between the ages of 15 and 17 (inclusive) provided that
Be willing to state that, to her best knowledge, her male sexual partner(s):
Exclusion Criteria:
Women ≥21 years of age with a Papanicolaou (pap) smear reading LGSIL or higher at screening (or six months prior to screening date). Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASC-US) can be used as an adjunctive test.
Known or to ingredients or of the IMP ( Medicinal Product), including:
Long-term treatment (longer than seven consecutive days within a month prior to V1b) of any medication that might interfere with the efficacy of hormonal contraceptives.
Prohibited medication include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single treatment arm receives LF111
Drug: LF111 (drospirenone)
One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Also known as: CF111
Number of Pregnancies (Evaluable Cycles)
Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment). The PI calculation was based on the following formula: PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300
Time frame: up to 13 months
Number of Pregnancies (All)
Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)
Time frame: up to 13 months
Number of Pregnancies (Method Failures)
PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)
Time frame: up to 13 months
Pregnancy Ratio
Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)
Time frame: up to 13 months
Overall PI, PI for Method Failures
Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)
Time frame: up to 13 months
Number of Participants With Adverse Events as a Measure of Safety
Adverse events and changes in vital signs, clinical laboratory parameters
Time frame: up to to 13 months
Tolerability; Vaginal Bleeding Pattern
Vaginal bleeding pattern
Time frame: up to 13 months
Number of Pregnancies (by BMI and Weight)
PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies
Time frame: up to 13 months
Overall Pregnancies
Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups
Time frame: up to 13 months
| Milestone | Drospirenone 4 mg |
|---|---|
| Started | 1552 |
| Completed | 352 |
| Not completed | 1200 |
| Withdrew: Lost to follow-up | 269 |
| Withdrew: Withdrawal by subject | 155 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Physician decision | 7 |
| Withdrew: Pregnancy | 15 |
| Withdrew: Wish for pregnancy | 5 |
| Withdrew: Development of an exclusion criteria | 16 |
| Withdrew: Adverse event | 113 |
| Withdrew: At the specific request of the sponsor | 20 |
| Withdrew: Several reasons not classified | 53 |
| Withdrew: Screening failures | 546 |
Pearl index (PI) from Evaluable Cycles in non-breastfeeding women aged ≤ 35 years (at the time of trial enrollment). The PI calculation was based on the following formula: PI(evaluable cycles)= (∑ on-drug confirmed pregnancy ∈{exposure cycles})/(#{exposure cycles} ) X 1300
| Pearl Index | Drospirenone 4 mg |
|---|---|
| Number of Pregnancies (Evaluable Cycles) | 2.9 (1.5 to 5.1) |
Pearl Index based on overall cycles (overall PI) in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)
| Pearl Index | LF111 (Drospirenone) |
|---|---|
| Number of Pregnancies (All) | 2.7 (1.4 to 4.7) |
PI for method failures in women aged ≤ 35 years (at the time of trial enrollment) (confirmed pregnancies)
| Pearl Index | LF111 (Drospirenone) |
|---|---|
| Number of Pregnancies (Method Failures) | 3.4 (1.4 to 7.0) |
Pregnancy ratio in women aged ≤ 35 years (at the time of trial enrollment)
| Cumulative Pregnancy Rate (%) | LF111 (Drospirenone) |
|---|---|
| Pregnancy Ratio | 2.46 (0.87 to 4.03) |
Overall PI, PI for method failures, PI (using evaluable cycles) and pregnancy ratio (life table analysis) in all women and in women up to 13 months (confirmed pregnancies)
| Pearl Index | LF111 (Drospirenone) |
|---|---|
| Overall PI, PI for Method Failures | 2.9 (1.2 to 6.1) |
Adverse events and changes in vital signs, clinical laboratory parameters
| Subjects | LF111 (Drospirenone) |
|---|---|
| Number of Participants With Adverse Events as a Measure of Safety | 667 |
Vaginal bleeding pattern
| Subjects with bleeding | LF111 (Drospirenone) |
|---|---|
| Tolerability; Vaginal Bleeding Pattern | 505 |
PI for evaluable cycles in women aged ≤ 35 years in total and by BMI and weight subgroups based on confirmed and on confirmed and suspected, non-confirmed pregnancies
| Pearl Index | LF111 (Drospirenone) |
|---|---|
| Pearl Index BMI<30 | 4.1 (2.0 to 7.3) |
| Pearl Index BMI>=30 | 2.9 (0.8 to 7.3) |
| Weight < Median | 5.1 (2.4 to 9.3) |
| Weight >= Median | 2.3 (0.8 to 5.5) |
Overall PI based on confirmed and on confirmed and suspected, non-confirmed pregnancies in total and by BMI and weight subgroups
| Pearl Index | LF111 (Drospirenone) |
|---|---|
| Pearl Index BMI<30 | 3.3 (1.7 to 6.0) |
| Pearl Index BMI>=30 | 2.3 (0.6 to 5.8) |
| Weight < Median | 4.2 (2.0 to 7.7) |
| Weight >= Median | 1.9 (0.6 to 4.4) |
Collected over 3 years. Non-serious events are listed at a 0.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Drospirenone 4mg | 0/1,006 (0%) | 17/1,006 (1.7%) | 341/1,006 (33.9%) |
| Event | Drospirenone 4mg |
|---|---|
| HYPERKALAEMIAMetabolism and nutrition disorders | 5/1006 |
| CHOLECYSTITIS ACUTEHepatobiliary disorders | 1/1006 |
| DRUG ABUSEPsychiatric disorders | 1/1006 |
| INTRACRANIAL ANEURYSMNervous system disorders | 1/1006 |
| APPENDICITISInfections and infestations | 1/1006 |
| ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions | 1/1006 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/1006 |
| OVERDOSEInjury, poisoning and procedural complications | 1/1006 |
| BILIARY COLICHepatobiliary disorders | 1/1006 |
| CELLULITISInfections and infestations | 1/1006 |
| Event | Drospirenone 4mg |
|---|---|
| MetrorrhagiaReproductive system and breast disorders | 52/1006 |
| HeadacheNervous system disorders | 47/1006 |
| DysmenorrhoeaReproductive system and breast disorders | 44/1006 |
| Breast painReproductive system and breast disorders | 43/1006 |
| NauseaGastrointestinal disorders | 40/1006 |
| Breast tendernessReproductive system and breast disorders | 30/1006 |
| AcneSkin and subcutaneous tissue disorders | 30/1006 |
| Weight increasedInvestigations | 23/1006 |
| MenorrhagiaReproductive system and breast disorders | 17/1006 |
| Vaginal haemorrhageReproductive system and breast disorders | 12/1006 |
1552 patients enrolled, 546 patients screening failures, 1006 patients analyzed, 352 patients completed
| Age, Customized(participants) | LF111 (Drospirenone 4mg) |
|---|---|
| <=35 years | 928 |
| >35 years | 78 |
| Sex: Female, Male(Participants) | LF111 (Drospirenone 4mg) |
|---|---|
| Female | 1006 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | LF111 (Drospirenone 4mg) |
|---|---|
| Hispanic or Latino | 229 |
| Not Hispanic or Latino | 777 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | LF111 (Drospirenone 4mg) |
|---|---|
| American Indian or Alaska Native | 13 |
| Asian | 20 |
| Native Hawaiian or Other Pacific Islander | 5 |
| Black or African American | 358 |
| White | 571 |
| More than one race | 0 |
| Unknown or Not Reported | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Oct 2017, 35 months.
Results were first posted in Jul 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Drospirenone